vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Silvercrest Asset Management Group Inc. (SAMG). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $32.0M, roughly 1.8× Silvercrest Asset Management Group Inc.). Silvercrest Asset Management Group Inc. runs the higher net margin — -0.4% vs -83.0%, a 82.6% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -0.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.7%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
RYTM vs SAMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $32.0M |
| Net Profit | $-47.5M | $-120.0K |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | -2.8% |
| Net Margin | -83.0% | -0.4% |
| Revenue YoY | 36.9% | -0.0% |
| Net Profit YoY | -9.6% | -107.4% |
| EPS (diluted) | $-0.73 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $32.0M | ||
| Q3 25 | $51.3M | $31.3M | ||
| Q2 25 | $48.5M | $30.7M | ||
| Q1 25 | $32.7M | $31.4M | ||
| Q4 24 | $41.8M | $32.0M | ||
| Q3 24 | $33.3M | $30.4M | ||
| Q2 24 | $29.1M | $31.0M | ||
| Q1 24 | $26.0M | $30.3M |
| Q4 25 | $-47.5M | $-120.0K | ||
| Q3 25 | $-52.9M | $618.0K | ||
| Q2 25 | $-46.6M | $1.9M | ||
| Q1 25 | $-49.5M | $2.5M | ||
| Q4 24 | $-43.3M | $1.6M | ||
| Q3 24 | $-43.6M | $2.3M | ||
| Q2 24 | $-32.3M | $2.7M | ||
| Q1 24 | $-141.4M | $3.0M |
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 88.6% | — | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | -2.8% | ||
| Q3 25 | -102.6% | 4.3% | ||
| Q2 25 | -93.4% | 13.2% | ||
| Q1 25 | -143.7% | 15.4% | ||
| Q4 24 | -98.6% | 6.1% | ||
| Q3 24 | -132.0% | 14.6% | ||
| Q2 24 | -139.2% | 17.1% | ||
| Q1 24 | -538.7% | 19.5% |
| Q4 25 | -83.0% | -0.4% | ||
| Q3 25 | -103.1% | 2.0% | ||
| Q2 25 | -96.1% | 6.3% | ||
| Q1 25 | -151.4% | 7.9% | ||
| Q4 24 | -103.6% | 5.1% | ||
| Q3 24 | -131.2% | 7.4% | ||
| Q2 24 | -110.9% | 8.6% | ||
| Q1 24 | -544.4% | 9.9% |
| Q4 25 | $-0.73 | $0.02 | ||
| Q3 25 | $-0.82 | $0.07 | ||
| Q2 25 | $-0.75 | $0.21 | ||
| Q1 25 | $-0.81 | $0.26 | ||
| Q4 24 | $-0.71 | $0.16 | ||
| Q3 24 | $-0.73 | $0.24 | ||
| Q2 24 | $-0.55 | $0.28 | ||
| Q1 24 | $-2.35 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $44.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $50.3M |
| Total Assets | $480.2M | $166.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $44.1M | ||
| Q3 25 | $416.1M | $36.1M | ||
| Q2 25 | $291.0M | $30.0M | ||
| Q1 25 | $314.5M | $36.3M | ||
| Q4 24 | $320.6M | $68.6M | ||
| Q3 24 | $298.4M | $58.1M | ||
| Q2 24 | $319.1M | $49.9M | ||
| Q1 24 | $201.2M | $39.7M |
| Q4 25 | $139.1M | $50.3M | ||
| Q3 25 | $148.8M | $58.9M | ||
| Q2 25 | $-11.9M | $64.6M | ||
| Q1 25 | $18.9M | $80.0M | ||
| Q4 24 | $21.7M | $80.7M | ||
| Q3 24 | $11.2M | $84.6M | ||
| Q2 24 | $39.3M | $85.3M | ||
| Q1 24 | $61.6M | $83.9M |
| Q4 25 | $480.2M | $166.6M | ||
| Q3 25 | $506.9M | $157.6M | ||
| Q2 25 | $372.7M | $152.7M | ||
| Q1 25 | $386.7M | $159.9M | ||
| Q4 24 | $392.3M | $194.4M | ||
| Q3 24 | $363.6M | $184.2M | ||
| Q2 24 | $381.8M | $177.6M | ||
| Q1 24 | $258.7M | $170.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $18.6M |
| Free Cash FlowOCF − Capex | — | $15.0M |
| FCF MarginFCF / Revenue | — | 46.9% |
| Capex IntensityCapex / Revenue | — | 11.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $17.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $18.6M | ||
| Q3 25 | $-26.6M | $14.6M | ||
| Q2 25 | $-23.3M | $13.8M | ||
| Q1 25 | $-40.4M | $-24.7M | ||
| Q4 24 | $-18.8M | $21.6M | ||
| Q3 24 | $-25.2M | $13.3M | ||
| Q2 24 | $-29.1M | $16.0M | ||
| Q1 24 | $-40.7M | $-24.1M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $13.4M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | — | $12.9M | ||
| Q2 24 | — | $15.6M | ||
| Q1 24 | — | $-24.7M |
| Q4 25 | — | 46.9% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | -80.0% | ||
| Q4 24 | — | 62.2% | ||
| Q3 24 | — | 42.4% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | — | -81.6% |
| Q4 25 | — | 11.4% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | — | -10.01× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | — | -8.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
